INTRODUCTION {#sec1-1}
============

Whole-slide imaging and digital image analysis have become commonplace in laboratory medicine and for the past decade many high-volume hematology laboratories have adopted semi-automated digital platforms for routine use.\[[@ref1]\] The CellaVision platforms are among the most thoroughly studied digital hematology platforms in use. Indeed, a review of the literature highlights the rigorous evaluation that the CellaVision system has undergone by multiple groups and from multiple perspectives: Several studies have supported the accuracy and precision of CellaVision for the purposes of the leukocyte differential;\[[@ref2][@ref3][@ref4][@ref5][@ref6][@ref7][@ref8][@ref9][@ref10][@ref11][@ref12][@ref13][@ref14][@ref15]\] others have highlighted the accuracy and precision of CellaVision in the analysis of red cell parameters;\[[@ref3][@ref4][@ref5][@ref11][@ref13][@ref16]\] others still have validated CellaVision for use in platelet counting and morphological assessment.\[[@ref3][@ref11][@ref13][@ref17]\] In reviewing the literature, only a single publication could be identified pertaining to the evaluation of digitized slide analysis for the purpose of reticulocyte counting;\[[@ref18]\] however, no CellaVision-specific data was identified.

Reticulocytes are immature erythrocytes released into the circulation just prior to the completion of their maturation; they can be identified by the presence of two or more basophilic intracytoplasmic granules corresponding to residual erythrocyte ribosomes\[[@ref19]\] (and usually only visible by supravital staining, with new methylene blue for example). The clinical utility of the identification and quantification of reticulocytes in the peripheral blood is considerable; reticulocytes are useful in the diagnostic work-up of anemia, in the subclassification of macrocytosis in certain contexts and in the assessment of response to treatments for anemia.\[[@ref19][@ref20][@ref21][@ref22]\] While the earliest identification techniques relied upon manual counts,\[[@ref19]\] in recent decades automated platforms have become the mainstay of reticulocyte assessment given more recent evidence of a lack of precision in manual assessments.\[[@ref19][@ref23]\] Nevertheless, a manual reticulocyte count remains a useful yardstick in the context of quality assurance.

As part of our laboratory\'s recent adoption of a holistic digital hematology system, we rigorously tested the CellaVision platform to ensure that it might be used under the most stringent clinical validation but also to its full methodological potential. Part of this validation process included a comparison of reticulocyte counts from manual, automated analyzer and CellaVision testing.

MATERIALS AND METHODS {#sec1-2}
=====================

This study was considered to constitute a quality assurance and laboratory validation project by our institution; and therefore, did not require formal research ethics board approval, as outlined by the Alberta Research Ethics Community Consensus Initiative (ARECCI) ethics guidelines.\[[@ref24]\] From each of the four hospital-based hematology laboratories in our laboratory network, series of consecutive patient blood samples were assessed; the number of sample selected was in keeping with previous data concerning correlation and sample size.\[[@ref25]\]

Standard analyzer testing was performed on a Beckman Coulter LH750 automated hematology analyzer (Beckman Coulter Canada LP) using the integrated new methylene blue approach, as previously described.\[[@ref26]\] The CellaVision (DM96, CellaVision, Lund, Sweden) and Manual percent reticulocyte counts were performed using supravital stained slides (produced by mixing equal aliquots of ethylenediaminetetraacetic acid-collected whole blood with new methylene blue) of the same samples analyzed by the LH750 platform. Manual percent reticulocyte counts were performed by a group of technologists from the individual sites of origin and based on a 200-erythrocyte total count. The CellaVision counts were obtained through automated (pre-classification) analysis only. In this process, the new methylene blue stained peripheral smear slides used in the manual counts were scanned and interpreted by CellaVision as part of its usual peripheral blood smear interpretation algorithm (no reticulocyte-specific protocol currently exists as part of the fully automated CellaVision algorithms). After pre-classification, technologist-assisted reticulocyte enumeration was performed; this count was taken as the CellaVision percent reticulocyte count. In addition, we did not adjust the reticulocyte counts for the degree of anemia as, for the purposes of method validation, we did not feel that this would provide significant information.

Percent reticulocyte counts were compared from among the three methods and data analyzed (by way of Spearman\'s rho correlation coefficients, Friedman\'s two-way Analysis Of Variance (ANOVA), bias mean and standard deviation) using Statistical Package for the Social Sciences software (SPSS Version 20, IBM); *P* values of less than 0.05 were considered significant.

RESULTS {#sec1-3}
=======

Twenty-five consecutive peripheral blood samples from each of our four hospital labs were included in the study sample (for a total of 100). Reticulocyte counts were recorded and plotted for all three methods \[Figures [1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}\]. There was significant correlation between the results of each method by Spearman\'s rho coefficient testing \[*P* \< 0.001; \[[Table 1](#T1){ref-type="table"}\]. Non-parametric testing for unrelated sample distributions was not significant by Friedman\'s two-way ANOVA (*P* = 0.086). R-squared values were calculated pairwise: LH750 vs. CellaVision R^2^ = 0.86; manual count vs. LH750 R^2^ = 0.75; manual count vs. CellaVision R^2^ = 0.78. Pair-wise bias was also calculated and compared \[[Table 2](#T2){ref-type="table"}\] using absolute values (given that a "true" value was not assumed *a priori*); these pair-wise distributions were not significantly different by Friedman\'s two-way ANOVA (*P* = 0.71). Notably, the mean and standard deviation of bias in comparing the LH750 vs. CellaVision were lower than the respective values when manual counts were compared with both the LH750 and CellaVision counts.
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Spearman\'s rho correlation coefficients for pair-wise comparisons of manual, LH750 analyzer and CellaVision % reticulocyte counts

![](JPI-5-17-g004)

###### 

Pairwise bias

![](JPI-5-17-g005)

DISCUSSION {#sec1-4}
==========

The CellaVision digital hematology platform has a well-validated track record for use in routine hematological laboratory practice. Published studies have reported a median leukocyte differential count accuracy of 90.3% in comparison to reference manual differentials.\[[@ref4][@ref5][@ref6][@ref7][@ref14]\] Others have reported a range of accuracy of pre-classification of erythrocyte morphological abnormalities from 65% to 98%, depending on the nature of the abnormality.\[[@ref16]\] Still others have evaluated platelet-counting concordance relative to standards, noting a range of correlation coefficients from 0.92 to 0.94.\[[@ref17]\] These data, in combination with evidence of potential substantial improvements in per-slide turn-around time,\[[@ref5]\] make the CellaVision platform an attractive option for the purposes of semi-automation of peripheral smear morphology interpretation.

For high-throughput hematology laboratories, reticulocyte counts can be accurately and cheaply assessed using automated hematology analyzers, with excellent turnaround times.\[[@ref26]\] In most cases, the use of CellaVision for the purposes of reticulocyte counting would likely not add a significant cost-benefit or turnaround time advantage (indeed, in our institution\'s experience, the average turnaround time for a CellaVision reticulocyte count is on par with that of a manual count; data not shown).

On the other hand, one can easily imagine scenarios in which reticulocyte counting using CellaVision might be a viable option. Let us consider, for example, the case of a small/rural low test-volume satellite laboratory without an available analyzer. When requested to perform a complete blood count (CBC) and reticulocyte count, rather than shipping the specimen, a peripheral smear could be produced and digitally scanned at the satellite site, the digital images (including one of a slide stained with new methylene blue) could be forwarded electronically to a larger referral laboratory, at which point all peripheral blood parameters (including the standard CBC and reticulocyte counts), as well as morphologic assessment, could be assessed and the data subsequently relayed back to the referring satellite laboratory. In such a scenario, the CellaVision holistic approach to digitized hematology might be an attractive option. When one considers the relative cost of purchase of a small analyzer capable of assessing reticulocyte counts and a CellaVision scanner, the above solution might indeed be a viable option for some; such automated analyzers have capital costs on par or greater than a comparable CellaVision system (based on CAP TODAY Hematology Analyzer Platform Product Comparisons.\[[@ref27]\]) Other potential benefits of the CellaVision system include real-time morphologically verifiable quality-assurance capabilities,\[[@ref1][@ref28]\] as well as the capacity for centralization of morphological expertise.\[[@ref1]\]
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